Regulation of tissue-degrading factors and in vitro invasiveness in progression of breast cancer cells

Clinical and Experimental Metastasis

Volumn 16, Issue 3, 1998, Pages 205-215

  Ree, Anne Hansen ^a,d   Bjørnland, Kristin ^b   Brünner, Nils ^c   Johansen, Harald Thidemann ^a   Pedersen, Kjetil Boye ^a   Aasen, Ansgar O ^b   Fodstad, Øystein ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c FINSEN LABORATORY   (Denmark)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Breast cancer; In vitro invasiveness; Metalloproteinase system; Urokinase system

Indexed keywords

MATRIX METALLOPROTEINASE; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE; UROKINASE;

ARTICLE; BREAST CANCER; CANCER INVASION; CELL STRAIN MCF 7; CONTROLLED STUDY; HUMAN; HUMAN CELL; NORTHERN BLOTTING; PROTEIN EXPRESSION; RNA ANALYSIS;

BREAST NEOPLASMS; CELL MOVEMENT; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; METALLOENDOPEPTIDASES; NEOPLASM INVASIVENESS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE C; RNA, MESSENGER; RNA, NEOPLASM; TETRADECANOYLPHORBOL ACETATE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0031953809     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006584624061     Document Type: Article

References (48)

1. Clarke R, Dickson RB and Brünner N, 1990, The process of malignant progression in human breast cancer. Ann Oncol, 1, 401-7.
2. Liotta LA, Steeg PS and Stetler-Stevenson WG, 1991, Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64, 327-36.
3. Brünner N, Pyke C, Holst-Hansen C, Rømer J, Grøndahl-Hansen J and Danø K, 1994, Urokinase plasminogen activator (uPA) and its type 1 inhibitor (PAI-1): regulators of proteolysis during cancer invasion and prognostic parameters in breast cancer. In: Dickson R and Lippman M, eds. Mammary tumorigenesis and malignant progression. Dordrecht: Kluwer Academic Publishers, pp. 299-309.
4. Salamonsen LA, 1996, Matrix metalloproteinases and their tissue inhibitors in endocrinology. Trends Endocrinol Metabolism, 7, 28-34.
5. Angel P, Baumann I, Stein B, Delius H, Rahmsdorf HJ and Herrlich P, 1987, 12-O-tetradecanoyl-phorbol-13-acetate induction of the human collagenase gene is mediated by an inducible enhancer element located in the 5′-flanking region. Mol Cell Biol, 7, 2256-66.
6. Sato H and Seiki M, 1993, Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene, 8, 395-405.
7. Campbell CE, Flenniken AM, Skup D and Williams BRG, 1991, Identification of a serum- and phorbol ester-responsive element in the murine tissue inhibitor of metalloproteinase gene. J Biol Chem, 266, 7199-206.
8. Suh TT, Nerlov C, Danø K and Degen JL, 1994, The murine urokinase-type plasminogen activator receptor gene. J Biol Chem, 269, 25992-8.
9. Knudsen H, Olesen T, Riccio A, Ungaro P, Christensen L and Andreasen PA, 1994, A common response element mediates differential effects of phorbol esters and forskolin on type-1 plasminogen activator inhibitor gene expression in human breast carcinoma cells. Eur J Biochem, 220, 63-74.
10. Issandou M, Bayard F and Darbon J-M, 1988, Inhibition of MCF-7 cell growth by 12-O-tetradecanoylphorbol-13-acetate and 1,2-dioctanoyl-sn-glycerol: distinct effects on protein kinase C activity. Cancer Res, 48, 6943-50.
11. Guilbaud NF, Gas N, Dupont MA and Valette A, 1990, Effects of differentiation-inducing agents on maturation of human MCF-7 breast cancer cells. J Cell Physiol, 145, 162-72.
12. Starzec AB, Spanakis E, Nehme A, et al. 1994, Proliferative responses of epithelial cells to 8-bromocyclic AMP and to a phorbol ester change during breast pathogenesis. J Cell Physiol, 161, 31-8.
13. Brünner N, Boulay V, Fojo A, Freter CE, Lippman ME and Clarke R, 1993, Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Res, 53, 283-90.
14. Thompson EW, Brünner N, Torri J, et al. 1993, The invasive and metastatic properties of hormone-independent but hormone-responsive variants of MCF-7 human breast cancer cells. Clin Exp Metastasis, 11, 15-26.
15. Clarke R, Brünner N, Thompson EW, et al. 1989, The inter-relationships between ovarian-independent growth, antiestrogen resistance and invasiveness in the malignant progression of human breast cancer. 0J Endocrinol. 122, 331-40.
16. Rømer J, Pyke C, Lund LR, et al. 1994, Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion. Int J Cancer, 57, 553-60.
17. Pyke C, Kristensen P, Ralfkiaer E, Eriksen J and Danø K, 1991, The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in the endothelial cells in the tumor stroma. Cancer Res, 51, 4067-71.
18. Makowski GS and Ramsby ML, 1996, Calibrating gelatin zymograms with human gelatinase standards. Anal Biochem, 236, 353-6.
19. Nunez A-M, Berry M, Imler J-L and Chambon P, 1989, The 5′-flanking region of the pS2 gene contains a complex enhancer region responsive to oestrogens, epidermal growth factor, a tumour promoter (TPA), the c-Ha-ras oncoprotein and the c-jun protein. EMBO J, 8, 823-9.
20. Albini A, Melchiori A, Santi L, Liotta LA, Brown PD and Stetler-Stevenson WG, 1991, Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst. 83, 775-9.
21. DeClerck YA, Perez N, Shimada H, Boone TC, Langley KE and Taylor SM, 1992, Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res, 52, 701-8.
22. Montgomery AMP, Mueller BM, Reisfeld RA, Taylor SM and DeClerck YA, 1994, Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res, 54, 5467-73.
23. Imren S, Kohn DB, Shimada H, Blavier L and DeClerck YA, 1996, Overexpression of tissue inhibitor of metalloproteinases-2 by retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion. Cancer Res, 56, 2891-5.
24. Mignatti P, Robbins E and Rifkin DB, 1986, Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell, 47, 487-98.
25. Schultz RM, Silberman S, Persky B, Bajkowski AS and Carmichael DF, 1988, Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells. Cancer Res, 48, 5539-45.
26. Khokha R, Waterhouse P, Yagel S, et al. 1989, Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. Science, 243, 947-50.
27. Tanaka K, Iwamoto Y, Ito Y, et al. 1995, Cyclic AMP-regulated synthesis of the tissue inhibitors of metalloproteinases suppresses the invasive potential of the human fibrosarcoma cell line HT1080. Cancer Res, 55, 2927-35.
28. Nabeshima K, Komada N, Kishi J, et al. 1993, TPA-enhanced invasion of Matrigel associated with augmentation of cell motility but not metalloproteinase activity in a highly metastatic variant (L-10) of human rectal adenocarcinoma cell line RCM-1. Int J Cancer, 55, 974-81.
29. van Leeuwen RL, Dekker SK, Arbiser JL, Vermeer BJ, Bruijn JA and Byers HR, 1994, Phorbol ester induced rapid attachment and spreading of melanoma cells and the role of extracellular matrix proteins. Int J Cancer, 57, 894-900.
30. Dickson RB, Shi YE and Johnson MD, 1994, Matrix-degrading proteases in hormone dependent breast cancer. Breast Cancer Res Treat, 31, 167-73.
31. Kawashima A, Nakanishi I, Tsuchiya H, Roessner A, Obata K and Okada Y, 1994, Expression of matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) induced by tumour necrosis factor a correlates with metastatic ability in a human osteosarcoma cell line. Virchows Archiv, 424, 547-52.
32. Rao JS, Steck PA, Tofilon P, et al. 1994, Role of plasminogen activator and of 92-kDa type IV collagenase in glioblastoma invasion using an in vitro Matrigel model. J Neuro-Oncol, 18, 129-38.
33. Kubota S, Takeda K, Yamada T, et al. 1996, Tumor necrosis factor alpha and lymphotoxin stimulate human myeloblastic leukemia cell (ML-1) invasion through a reconstituted basement membrane (Matrigel) with concomitant induction of 92 kDa gelatinase secretion. Cancer Lett, 98, 233-40.
34. Liu G, Shuman MA and Cohen RL, 1995, Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int J Cancer, 60, 501-6.
35. Holst-Hansen C, Johannessen B, Høyer-Hansen G, Rømer J, Ellis V and Brünner N, 1996, Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis, 14, 297-307.
36. Deng G, Curriden SA, Wang S, Rosenberg S and Loskutoff DJ, 1996, Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol, 134, 1563-71.
37. 3 binding to vitronectin. Nature, 383, 441-3.
38. Schnaper HW, Grant DS, Stetler-Stevenson WG, et al. 1993, Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro. J Cell Physiol, 156, 235-46.
39. Schnaper HW, Barnathan ES, Mazar A, et al. 1995, Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways. J Cell Physiol, 165, 107-18.
40. Ito K-I, Ryuto M, Ushiro S, et al. 1995, Expression of tissue-type plasminogen activator and its inhibitor couples with development of capillary network by human microvascular endothelial cells on Matrigel. J Cell Physiol, 162, 213-24.
41. Bae S-N, Arand G, Azzam H, et al. 1993, Molecular and cellular analysis of basement membrane invasion by human breast cancer cells in Matrigel-based in vitro assays. Breast Cancer Res Treat, 24, 241-55.
42. 1-Antitrypsin-and anchorage-independent growth of MCF-7 breast cancer cells. Endocrinology, 133, 996-1002.
43. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, et al. 1993, High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res, 53, 2513-21.
44. Jänicke F, Schmitt M, Pache L, et al. 1993, Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat, 24, 195-208.
45. Foekens JA, Schmitt M, van Putten WLJ, et al. 1994, Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol, 12, 1648-58.
46. Bianchi E, Cohen RL, Dai A, Thor AT, Shuman MA and Smith HS, 1995, Immunohistochemical localization of the plasminogen activator inhibitor-1 in breast cancer. Int J Cancer, 60, 597-603.
47. Clarke R, Skaar T, Baumann K, et al. 1994, Hormonal carcinogenesis in breast cancer: cellular and molecular studies of malignant progression. Breast Cancer Res Treat, 31, 237-48.
48. Foekens JA, Look MP, Peters HA, van Putten WLJ, Portengen H and Klijn JGM, 1995, Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst, 87, 751-6.